Filing identity and reporting period
Important identity mismatch: The supplied filing is Petra Acquisition, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2021—not a filing by Revelation Biosciences, Inc. It describes a blank-check company searching for a business combination, not a biotechnology operating business.
Financial results and liquidity
- Revenue: None. Petra had not commenced operations and expected no operating revenue before a business combination.
- Results: Net income was $1.178 million, versus a $7,160 net loss in Q1 2020. Q1 2021 included $468,861 of general and administrative expense and a $1.662 million noncash gain from the change in fair value of warrant liabilities. Operating loss was $468,861. Margins are not meaningful without revenue.
- Cash flow: Operating cash outflow was $146,372; investing cash inflow was $134,638; cash declined $11,734 to zero. The filing reports no financing cash flow for Q1 2021.
- Assets and liquidity at March 31: $390,649 of marketable securities outside the trust, $124,513 of prepaid expenses, and $73.513 million in the trust account. Accounts payable and accrued liabilities were $383,635; warrant liability was $1.738 million; total liabilities were $5.032 million. Working capital deficiency was approximately $1.606 million.
- Debt and commitments: No long-term debt was reported. Deferred underwriting commissions were $2.911 million, payable only if a business combination is completed. A separate business-combination marketing fee of 4% of IPO gross proceeds is also contingent on completion.
Changes, outlook, and risks
- Compared with Q1 2020, general and administrative expense increased from $7,160 to $468,861, while reported results moved from a small loss to income, primarily because of the warrant-liability fair-value gain—not operating growth.
- The company was required to complete a business combination within 12 months of the October 13, 2020 IPO, or liquidate and redeem public shares. It described a qualifying transaction as generally requiring a target with fair market value of at least 80% of trust assets at agreement signing. Management said available resources were expected to cover needs through a business combination or one year from the filing.
- Management cautioned that a transaction was not assured and that additional financing might be needed. Public-share redemptions, dilution from new securities, and potential debt financing were identified as relevant risks. Warrants could expire worthless if no transaction is completed.
- The company disclosed a material weakness in disclosure controls related to the restatement of prior financial statements to classify derivative warrants as liabilities. Controls were therefore considered ineffective as of March 31; remediation was planned, with no assurance it would succeed.
- Subsequent event: Nasdaq notified Petra on May 28, 2021 that it was not compliant with a filing-timeliness rule because this Form 10-Q had not been filed; the notice gave until July 26 to submit a compliance plan and had no immediate effect on listing.
Important facts to verify
- Confirm the intended issuer: the provided filing identifies Petra Acquisition, Inc., not Revelation Biosciences, Inc.
- Reconcile the warrant gain: the financial statements report $1,662,373, while MD&A states $1,622,373.
- Reconcile other apparent text inconsistencies, including the cash-flow statement’s $1,178,184 net-income figure versus $1,178,194 in the income statement, and conflicting transaction-cost/deferred-fee amounts in the narrative.
- Verify the business-combination deadline, trust balance and any subsequent transaction or redemption developments; this filing reports information only through March 31, 2021, with the Nasdaq notice disclosed subsequently.